All In Biotech

Drug Trial Radar · NCT07391657

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

508

Planned (sponsor's estimate)

Start

Feb 23, 2026

Primary completion

Jun 14, 2028

Study completion Jul 29, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

Conditions

  • Relapsed Refractory Multiple Myeloma

Interventions

  • AZD0120Biological

    CAR-T Cells

  • DaratumumabDrug

    Daratumumab

  • CarfilzomibDrug

    Carfilzomib

  • DexamethasoneDrug

    Dexamethasone

  • BortezomibDrug

    Bortezomib

  • PomalidomideDrug

    Pomalidomides

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.Time frame: 3 years
  2. To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.Time frame: 2 years

Locations

143 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona · Not yet recruiting

  • Research Site

    Phoenix, Arizona · Withdrawn

  • Research Site

    Tucson, Arizona · Not yet recruiting

  • Research Site

    La Jolla, California · Withdrawn

  • Research Site

    Sacramento, California · Not yet recruiting

  • Research Site

    Santa Monica, California · Not yet recruiting

  • Research Site

    Denver, Colorado · Recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Not yet recruiting

  • Research Site

    Coral Gables, Florida · Withdrawn

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Park Ridge, Illinois · Not yet recruiting

  • Research Site

    Iowa City, Iowa · Withdrawn

  • Research Site

    Kansas City, Kansas · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Rochester, Minnesota · Withdrawn

  • Research Site

    Albany, New York · Not yet recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Rochester, New York · Withdrawn

  • Research Site

    The Bronx, New York · Withdrawn

  • Research Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Research Site

    Charlotte, North Carolina · Not yet recruiting

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Winston-Salem, North Carolina · Recruiting

  • Research Site

    Winston-Salem, North Carolina · Not yet recruiting

  • Research Site

    Cincinnati, Ohio · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Charleston, South Carolina · Withdrawn

  • Research Site

    Nashville, Tennessee · Recruiting

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.